Ophthalmology. Retina · 2026
Pharmacologic Interventions for the Prevention and Treatment of Proliferative Vitreoretinopathy: A Systematic Review and Meta-Analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Burak Salem Abu, Alizada Ameen, Sadek Kareem, Aleshawi Abdelwahab, Al-Dwairi Rami, Abu Serhan Hashem
Аннотация
TOPIC: To evaluate the efficacy and safety of pharmacologic interventions (including 5-fluorouracil, low-molecular-weight heparin, methotrexate, corticosteroids, anti-VEGF agents, and retinoids) compared with control treatments for preventing or treating proliferative vitreoretinopathy (PVR) after rhegmatogenous retinal detachment repair.
CLINICAL RELEVANCE: PVR is the leading cause of anatomic failure after retinal detachment surgery. Despite advances in vitreoretinal techniques, no pharmacologic adjuvant has been established, and management remains primarily surgical.
METHODS: We registered our protocol with PROSPERO (CRD420261435402). We systematically searched 4 databases from inception to June 2026 for studies evaluating pharmacologic therapies for PVR prevention or treatment. Risk of bias was assessed using validated tools, and random-effects meta-analyses were performed to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: In total, 69 studies were included, with 31 contributing to the meta-analysis. No significant improvement in anatomic outcomes was observed with 5-fluorouracil plus low-molecular-weight heparin for prevention (RR, 0.94; 95% CI, 0.59-1.51), methotrexate for established PVR (RR, 0.96; 95% CI, 0.86-1.07), corticosteroids (RR, 1.11; 95% CI, 0.93-1.33), or anti-VEGF therapy (RR, 0.72; 95% CI, 0.32-1.64). Overall, pharmacologic therapy was associated with reduced redetachment risk (RR, 0.52; 95% CI, 0.28-0.94), mainly driven by methotrexate and anti-VEGF subgroups. Retinoids showed a potential benefit for reattachment. Certainty of evidence was low to very low.
CONCLUSION: Current evidence does not support routine pharmacologic adjuvant therapy for PVR. Methotrexate, anti-VEGF agents, and retinoids show promising signals but require confirmation in adequately powered randomized controlled trials.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
CLINICAL RELEVANCE: PVR is the leading cause of anatomic failure after retinal detachment surgery. Despite advances in vitreoretinal techniques, no pharmacologic adjuvant has been established, and management remains primarily surgical.
METHODS: We registered our protocol with PROSPERO (CRD420261435402). We systematically searched 4 databases from inception to June 2026 for studies evaluating pharmacologic therapies for PVR prevention or treatment. Risk of bias was assessed using validated tools, and random-effects meta-analyses were performed to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: In total, 69 studies were included, with 31 contributing to the meta-analysis. No significant improvement in anatomic outcomes was observed with 5-fluorouracil plus low-molecular-weight heparin for prevention (RR, 0.94; 95% CI, 0.59-1.51), methotrexate for established PVR (RR, 0.96; 95% CI, 0.86-1.07), corticosteroids (RR, 1.11; 95% CI, 0.93-1.33), or anti-VEGF therapy (RR, 0.72; 95% CI, 0.32-1.64). Overall, pharmacologic therapy was associated with reduced redetachment risk (RR, 0.52; 95% CI, 0.28-0.94), mainly driven by methotrexate and anti-VEGF subgroups. Retinoids showed a potential benefit for reattachment. Certainty of evidence was low to very low.
CONCLUSION: Current evidence does not support routine pharmacologic adjuvant therapy for PVR. Methotrexate, anti-VEGF agents, and retinoids show promising signals but require confirmation in adequately powered randomized controlled trials.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.